Interleukin-17A Antagonists [MoA] - N0000191494

Pharmacologic Class Information

Pharmacologic Code N0000191494
Pharmacologic Name Interleukin-17A Antagonists
Pharmacologic Uses
  • humanized interleukin-17A antagonist
  • interleukin-17A antagonist
Pharmacologic Concept Mechanisms of Action - [MoA]
Pharmacologic Concept Description This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

NDC Products with Interleukin-17A Antagonists

The table contains 8 products whose active ingredient are classified under the same pharmacologic class Interleukin-17A Antagonists [MoA].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
0002-7724Taltz Non-Proprietary Name: IxekizumabInjection, SolutionSubcutaneousEli Lilly And CompanyACTIVE
0078-1168Cosentyx Non-Proprietary Name: SecukinumabInjection, Solution, ConcentrateIntravenousNovartis Pharmaceuticals CorporationACTIVE
0078-0639Cosentyx Non-Proprietary Name: SecukinumabInjectionSubcutaneousNovartis Pharmaceuticals CorporationACTIVE
0078-1070Cosentyx Non-Proprietary Name: SecukinumabInjectionSubcutaneousNovartis Pharmaceuticals CorporationACTIVE
0078-1056Cosentyx Non-Proprietary Name: SecukinumabInjectionSubcutaneousNovartis Pharmaceuticals CorporationACTIVE
0002-8900Taltz Non-Proprietary Name: IxekizumabInjection, SolutionSubcutaneousEli Lilly And CompanyACTIVE
0002-8905Taltz Non-Proprietary Name: IxekizumabInjection, SolutionSubcutaneousEli Lilly And CompanyACTIVE
0002-1445Taltz Non-Proprietary Name: IxekizumabInjection, SolutionSubcutaneousEli Lilly And CompanyACTIVE